Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Progression-Free Survival Cut It In Brave New Melanoma World?

Executive Summary

The changing landscape for melanoma drugs raises questions about the appropriateness of overall survival as a trial endpoint and the ethics of using old drugs like the chemotherapy dacarbazine as “standard of care” comparators in pivotal studies.

You may also be interested in...



Yervoy Approval Has Shifted Development Landscape For Melanoma

With Bristol-Myers Squibb Co.’s ipilimumab cleared and Roche/Daiichi Sankyo’s BRAF inhibitor vemurafenib (RG7204) on track for a filing and perhaps approval this year, companies developing other melanoma drugs face a more complicated, competitive path to market.

Drug Developers Ask For Flexible Combinations In Co-Development Regulation

Drug makers responding to FDA's draft guidance on co-development of novel drugs to be used in combination asked the agency to loosen up the boundaries on what kinds of products can be combined, particularly in light of the requirement that the products be aimed only at serious and life-threatening diseases for which there are no satisfactory alternatives.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel